Predictors of response to sertraline in patients with major depression

Human Psychopharmacology

Volumn 23, Issue 8, 2008, Pages 647-651

  Morishita, Shigeru ^a,b   Kinoshita, Toshihiko ^b  

^a Kyoto Jujo Rehabilitation Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Age; Antidepressant; Major depression; Sertraline; Sex; SSRI

Indexed keywords

SERTRALINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COGNITIVE THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME; AGE; DOSE RESPONSE; GENETIC PREDISPOSITION; GENETICS; HOSPITAL; JAPAN; MIDDLE AGED; REHABILITATION CENTER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS; HUMANS; JAPAN; MALE; MIDDLE AGED; REHABILITATION CENTERS; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60849111420     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.969     Document Type: Article

References (30)

1. American Psychiatric Association. 1994. Quick Reference to the Diagnostic Criteria from DSM-IV. American Psychiatric Press: Washington D.C.
2. Baca E, Garca-Garcia M, Porras-Chavarion A. 2004. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 28: 57-65. DOI: 10.1016/S0278-5846(03)00177-5
3. Berlanga C, Flores-Ramos M. 2006. Different gender response to serononergic and noradrenergic antidepressants. A Comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95: 119-123. DOI: 10.1016/j.jad.2006.04.029
4. Bondareff W, Alpert M, Friedhoff AJ, Richter EM, Clary CM, Batzar E. 2000. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 157: 729-736.
5. Cantrell R, Gillespine W, Altshuler L. 1999. Fluoxetine and sertraline dosage in major depression. Depress Anxiety 9: 78-82.
6. Doogan DP, Caillard V. 1988. Sertraline: a new antidepressant. J Clin Psychiatry 49 (suppl): 46-51.
7. Gex-Fabry M, Balant-Gorgia AE, Balant LP. 1999. Clomipramine concentration as a predictor of delayed response: a naturalistic study. Eur J Clin Pharmacol 54: 895-4902.
8. Halbreich U, Kahn LS. 2001. Role of estrogen in the ethiology and treatment of mood disorders. CNS Drugs 15: 797-817.
9. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
10. Joyce PR, Mudler RT, Luty SE, McKenzie JM, Rae AM. 2003. A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 108: 20-23.
11. Kessler RC, McGonagle KA, Zhao S, et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8-19.
12. Koe BK, Weissman A, Welch WM, Brown RG. 1983. Sertraline, IS,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tertahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 226: 686-700.
13. Kornstein SG, Schatzberg AF, Thase ME, et al. 2000. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157: 1445-1452.
14. Martenyi F, Dossenbach M, Mrazk K, Metcalfe S. 2001. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition proffle. Eur Neuropsychopharmacol 11: 227-232.
15. McGrath PJ, Stewart JW, Petkova E, et al. 2000. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J. Clin Psychiatry 61: 518-524.
16. Moller HJ. 2000. Are all antidepressants the same? J Clin Psychiatry 61: 24-28.
17. Morishita S, Arita S. 2003a. Possible predictor of response to fluvoxamine for depression. Hum Psychopharmacol Clin Experimental 18: 197-200. DOI: 10.1002/hup. 469
18. Morishita S, Arita S. 2003b, Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Hum Psychopharmacol Clin Experimental 18: 479-482. DOI:10.1002/ hup.508
19. Morishita S, Arita S. 2003c. The clinical use of milnacipran for depression. Eur Psychiatry 18: 34-35. DOI: 10.1016/ S0924-9338(02)00.003-2
20. Morishita S, Arita S. 2004. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum Psychopharmacol Clin Experimental 19: 405-408. DOI: 10.1002/hup. 608
21. Morishita S, Arita S. 2005. Possible predictors of response to paroxetine for depression. Int Med J 12: 271-273.
22. Navarro V, Gasto C, Torres X, Marcos T, Pinto L. 2001. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 103: 435-440.
23. Panzaro PJ. 1998. The cost of depression: direct and indirect; treatment versus nontreatment. J Clin Psychiatry 59 (suppl 20): 11-14.
24. Preskom SH, Lane RM. 1995. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 10: 129-141.
25. Prien RF, Carpenter LL, Kupfer DJ. 1991. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 48: 796-800.
26. Quitkin FM, McGrath PJ, Stewart JW, et al. 1996. Chronological milestones to guide drug change: when should clinicians switch antidepressant? Arch Gen Psychiatry 53: 785-792.
27. Rush AJ, Trivedi M, Fava M. 2003. Dipression IV: STAR*D treatment trial for depression. Am J Psychiatry 160: 237.
28. Stassen HH, Angst J, Delini-Stula A. 1994. Severity of baseline and onset of improvement in depression: meta-analysis of imipramine and mochlobemide versus placebo. Eur Psychiatry 9 (suppl 3): 129-136.
29. Sussman N. 2007. Translating science into service: lessons learned from the sequenced treatment alternative to relieve depression study. Prim Care Companion J Clin Psychiatry 9: 331-337.
30. Thase ME, Entsuah R, Cantillon M, Kornstein SG. 2005. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interaction. J Womens Health 14: 609-616.